Relieves discomfort associated with acute, painful musculoskeletal conditions. ANDA 203374, held by Sciegen Pharms. Carisoprodol.
As of Nov 16, 2026, ANDA 203374 (Carisoprodol), held by Sciegen Pharms, was first approved by FDA on Jan 27, 2014, with 1 approved supplement and 0 published complete response letters.
Carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use Carisoprodol should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration..
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 27, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Carisoprodol350MG · tablet;oral | Carisoprodol | Rx |
| Apr 2, 2019 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jan 27, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters